Zikani Therapeutics: Funding, Investors & Team (Nov 2026)
Zikani Therapeutics are among the most widely used, most effective, and safest antibiotics to reach clinical practice; in fact, azithromycin has been among the world’s most widely used antibiotics for the past several years. But, while current macrolides are highly effective against some major bacteria, they are ineffective against others, especially gram-negative bacteria, the cause of most serious infections in the US. The first three generations of macrolides have very limited activity against gram-negative, and the sole drug in the current fourth-generation, solithromycin, has only slightly greater activity. Within other antibiotic classes, a limited number of compounds are in development to treat resistant gram-negative infections, and even fewer are available both intravenously and orally, as would be expected with macrolides. The company was founded in 2014 and is headquartered in Newton, Massachusetts.
Zikani Therapeutics has raised $7.5M across 1 funding round on record, the most recent an undisclosed round of $7.5M announced in Apr 2020.
That round is below the $8.8M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Zikani Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2020.
Zikani Therapeutics Funding Rounds
Zikani Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Zikani Therapeutics Funding Compared to Other Biotechnology Startups
Zikani Therapeutics' latest round of $7.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Zikani Therapeutics in Biotechnology and Newton
Companies Similar to Zikani Therapeutics
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus…
Zafrens, a pharmaceutical research organization, focuses on designing life sciences solutions for…
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates to target driver oncogenes.…
Arctic Therapeutics specializes in finding the genetic origins of common diseases and creating successful…
100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to…
MEND is a company focused on life sciences, determined to assist individuals in achieving better health…
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Zikani Therapeutics Funding FAQs
What does Zikani Therapeutics do?
Zikani Therapeutics are among the most widely used, most effective, and safest antibiotics to reach clinical practice; in fact, azithromycin has been among the world’s most widely used antibiotics for the past several years. But, while current macrolides are highly effective against some major bacteria, they are ineffective against others, especially gram-negative bacteria, the cause of most serious infections in the US. The first three generations of macrolides have very limited activity against gram-negative, and the sole drug in the current fourth-generation, solithromycin, has only slightly greater activity. Within other antibiotic classes, a limited number of compounds are in development to treat resistant gram-negative infections, and even fewer are available both intravenously and orally, as would be expected with macrolides. The company was founded in 2014 and is headquartered in Newton, Massachusetts.
How much funding has Zikani Therapeutics raised?
Zikani Therapeutics has raised $7.5M across 1 round on record. The most recent is an undisclosed round of $7.5M announced in Apr 2020.
When did Zikani Therapeutics last raise funding?
Zikani Therapeutics' most recent funding round on record is an undisclosed round of $7.5M, announced in Apr 2020.
Who is the CEO of Zikani Therapeutics?
Sumit Aggarwal is listed as CEO at Zikani Therapeutics.
Where is Zikani Therapeutics headquartered?
Zikani Therapeutics is based in Newton, Massachusetts, United States.
How many employees does Zikani Therapeutics have?
Zikani Therapeutics is in the 11-50 employee band.
How does Zikani Therapeutics' funding compare to other Biotechnology startups?
Zikani Therapeutics' latest round of $7.5M is below the $8.8M median round size for Biotechnology companies on FundedIQ across 4,188 tracked companies over the last two years.
About FundedIQ's Zikani Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Zikani Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.